A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Blepharitis
- Focus Therapeutic Use
- Sponsors InSite Vision
- 15 Jun 2017 Planned number of patients changed from 300 to 550.
- 15 Jun 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
- 15 Jun 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.